Summary of Study ST002355
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001512. The data can be accessed directly via it's Project DOI: 10.21228/M8812G This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002355 |
| Study Title | Stool short chain fatty acid (SCFA) levels in peanut allergy |
| Study Summary | Prior evidence supports differential levels of short chain fatty acids in the stool of human beings with allergy and murine models of allergy. Here we performed a targeted study of selected short chain fatty acid levels in stool samples collected from children with allergy risk factors. Sample processing included homogenization of stool samples, inclusion of internal standards, and derivitization for liquid chromatography tandem mass spectrometry. |
| Institute | Icahn School of Medicine at Mount Sinai |
| Last Name | Bunyavanich |
| First Name | Supinda |
| Address | 1 Gustave L. Levy Pl, New York, NY 10029 |
| supinda.bunyavanich@mssm.edu | |
| Phone | Stool metabolite levels in individuals with peanut allergy were measured. |
| Submit Date | 2022-11-08 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-12-08 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002437 |
| Collection Summary: | Participants of this study included 122 children from the multi-center NIAID Consortium for Food Allergy Research (CoFAR) Observational Study (CoFAR2) who provided stool samples at both infancy and mid-childhood (these are the factors listed in the table). The recruitment and clinical characteristics of these CoFAR2 subjects have been previously described. Briefly, 511 children were recruited at age 3 to 15 months from five US sites (New York, NY, Baltimore, MD, Little Rock, AR, Denver, CO, Durham, NC).16 The cohort was designed as a longitudinal study of infants at high risk for developing peanut allergy, and inclusion criteria included likely egg allergy, milk allergy, and/or moderate to severe atopic dermatitis with a positive egg and/or milk skin prick test at enrollment, but no known peanut allergy. 16 Clinical phenotyping of the subjects, including assessments of peanut allergy, egg allergy, milk allergy, and atopic dermatitis, were performed at 6-12 month intervals between enrollment at infancy and mid-childhood (mean age 9 years, SD 0.6 years). All subjects provided stool samples at baseline and were invited to submit a follow up sample at mid-childhood. Stool samples were collected from 492 of the children at baseline and from 122 of the children at mid-childhood. Samples were immediately stored at -80 o C upon receipt. |
| Sample Type: | Feces |
